Zura Bio says Phase 2 TibuSHIELD study of tibulizumab in hidradenitis suppurativa missed primary and key secondary endpoints

Zura Bio says its Phase 2 TibuSHIELD study of tibulizumab in hidradenitis suppurativa missed the primary and key secondary endpoints.

Detected & updated continuously · Source: Nebula